Zachary Orme, DO
Family Medicine · Chester, ILNPI 1548880818
Payments from drug & device makers
Across 61 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$382
- AstraZeneca$96
- Indivior Inc.$91
- Sumitomo Pharma America, Inc.$71
- Otsuka America Pharmaceutical, Inc.$65
- Dexcom, Inc.$60
- plus $456 from 14 others
What the payments were for
- Food & beverage$1,222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $382 |
| AstraZeneca | 6 | $96 |
| Indivior Inc. | 4 | $91 |
| Sumitomo Pharma America, Inc. | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Dexcom, Inc. | 2 | $60 |
| Alkermes, Inc. | 3 | $60 |
| Boehringer Ingelheim | 3 | $58 |
| Exact Sciences | 3 | $56 |
| Sanofi Pasteur Inc. | 2 | $51 |
| Merck | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| AbbVie | 1 | $29 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Novartis | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
How this compares
$1,222 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 41 | $3,368 |
| Levothyroxine Sodium | 29 | $605 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $287 |
| Doxycycline Hyclate | 33 | $258 |
| Losartan Potassium | 22 | $170 |
| Atorvastatin Calcium | 26 | $151 |
| Gabapentin | 14 | $146 |
| Fluticasone Propionate | 16 | $141 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $138 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $130 |
| Pantoprazole Sodium | 17 | $76 |
| Tizanidine Hcl | 14 | $61 |
| Clonidine Hcl | 11 | $50 |
| Furosemide | 14 | $49 |
| Amlodipine Besylate | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Chester
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.